At a glance
- Originator Northern Institute for Cancer Research
- Class Antineoplastics; Hypoxanthines; Small molecules
- Mechanism of Action Cyclin-dependent kinase 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in United Kingdom
- 18 May 2007 Data presented at the 98th Annual Meeting of the American Association for Cancer Research (AACR-2007) added to the Cancer pharmacodynamics section
- 18 Apr 2007 Preclinical trials in Cancer in United Kingdom (unspecified route)